U.S. Biotech Stock News

Ralph Lauren Corporation recently appointed Cesar Conde, Chairman of NBCUniversal News Group and a current Walmart and PepsiCo director, to its 12-member Board, while investors are also watching for the company’s upcoming fiscal third-quarter 2026 earnings release with analysts expecting double-digit earnings growth. The combination of a high-profile media leader joining the Board and continued optimism around earnings and brand momentum is sharpening attention on how Ralph Lauren is...

Recent commentary on The St. Joe Company highlights how migration to Florida’s panhandle and scarce beach-adjacent land have supported higher lot prices and reinforced demand for its upper-middle-class coastal communities. At the same time, consistent share repurchases and a dividend increase have signaled management’s confidence in the durability of the company’s cash flows, strengthening its appeal to income-focused investors. Next, we’ll examine how these demand trends and capital return...

Intro Kinsale Capital Group (KNSL) has been drawing attention after recent share price moves, with the stock showing mixed returns over the past year while still carrying a multi year track record that some investors are reviewing closely. See our latest analysis for Kinsale Capital Group. Recent trading has been choppy, with a 1 day share price return of 0.85% and a 30 day share price return of 3.72%, set against a 90 day share price decline of 10.72%. The 5 year total shareholder return of...

FTI Consulting (FCN) has been active on the hiring front, bringing in senior leaders across cybersecurity and communications, a cluster of moves that highlights its advisory depth and event driven capabilities for investors. See our latest analysis for FTI Consulting. Those senior hires come as FTI Consulting’s share price has shown firmer momentum in recent months, with a 16.63% 3 month share price return and a 3.92% 1 month share price return, even though the 1 year total shareholder return...

In early January 2026, BioNTech outlined past and planned steps to evolve into a multi-product oncology company, highlighting more than 25 ongoing Phase 2 and 3 trials, plans for six additional Phase 3 starts in 2026, and multiple collaborations with BMS, Genentech, OncoC4, DualityBio, and MediLink. The company’s intention to reach 15 Phase 3 studies in 2026 and pursue at least 17 late-stage data readouts by 2030+ signals a broad push to build a diversified oncology portfolio spanning...

Phillips 66 (PSX) is back in focus after announcing a second open season for the proposed Western Gateway Pipeline with Kinder Morgan, which would expand refined product routes into Arizona, Nevada, and key California markets. See our latest analysis for Phillips 66. The Western Gateway news lands after a period where Phillips 66’s share price has had a 6.25% 1 month share price return and an 8.31% 3 month share price return, while the 1 year total shareholder return of 21.43% and 5 year...

Structure Therapeutics recently reported encouraging mid‑stage data for its oral obesity pill aleniglipron, showing double‑digit weight loss at higher doses over 36 weeks, and has also initiated the first human trial of ACCG‑2671, an oral small‑molecule amylin receptor candidate for obesity. Alongside these clinical advances, the company closed a public offering that raised about US$748,000,000 in gross proceeds, reinforcing investor backing for its expanding obesity drug pipeline despite...

Chewy (CHWY) is back on investors’ radar after Viking Global Investors sharply increased its stake, a move that coincided with a mid single digit share price jump and fresh attention on the stock’s recent pullback. See our latest analysis for Chewy. Viking’s move comes after a tougher stretch for existing holders, with a 90 day share price return showing a 12.47% decline and a 1 year total shareholder return showing a 12.07% decline. This suggests momentum has been fading even as interest in...

Wondering whether Getty Realty at around US$30.15 is offering good value right now, or if the recent interest has already been priced in. The stock has returned 6.7% over the last week, 6.0% over the past month, 9.4% year to date, 4.0% over 1 year, 4.0% over 3 years, and 50.2% over 5 years, which gives you a sense of how it has behaved recently and over a longer stretch. Recent news flow around Getty Realty has focused on its position in the US real estate sector and how investors are...

Why Campbell's (CPB) is back on investors’ radar Recent commentary around Campbell's (CPB) has focused on its valuation, with investors weighing the company’s premium brands, integration of Rao’s, and efforts to handle tariffs and inflation against ongoing cost and margin pressures. See our latest analysis for Campbell's. At a share price of US$26.90, Campbell's has had a softer run recently, with a 30-day share price return of 6.21% decline and a 1-year total shareholder return of 28.01%...

If you have been wondering whether Targa Resources at around US$181.93 is offering fair value or a potential bargain, you are not alone. The stock is up 2.9% over the last week and 3.1% over the past month, even though the year to date return is a 2.6% decline and the 1 year return is a 12.7% decline. Over 3 years the gain is 160%, and over 5 years the return is a very large increase. Recent attention on Targa Resources has focused on how the company is positioned within the US energy...

If you are trying to figure out whether eToro Group at around its recent price of US$31.27 looks like a bargain or a trap, you are in the right place. The stock has been under pressure lately, with a 3.9% decline over the last 7 days and a 13.2% decline across the past month, contributing to a 12.4% decline year to date. Recent headlines around eToro Group have focused on its position in online trading and investing, including ongoing interest in platforms that give retail investors easier...

Vulcan Materials (VMC) has been drawing fresh attention as analysts highlight its role in US infrastructure and investors weigh this sentiment against recent insider selling, which includes share sales by the company’s president. See our latest analysis for Vulcan Materials. At a share price of $301.71, Vulcan Materials has had a relatively steady run, with a 30 day share price return of 3.32% and a 1 year total shareholder return of 12.92%. The 3 year total shareholder return of 74.76%...

Belden Inc. has completed a €450 million offering of 4.250% senior subordinated Eurobonds due 2033 at par, with the proceeds earmarked to redeem its 3.375% senior subordinated notes due 2027 and cover related costs. By extending the maturity profile of its subordinated debt while keeping the issue priced at 100% of principal, Belden is reshaping its capital structure and potentially increasing financial flexibility for its ongoing digital infrastructure initiatives. We’ll now examine how...

If you are wondering whether GlobalFoundries is reasonably priced or offering value at its recent levels, this article will walk through what the numbers actually say. The share price last closed at US$41.53, with returns of 6.7% over the past week, 12.0% over the last 30 days, 12.6% year to date, and 1.5% over the past year, while the 3 year return stands at a 25.2% decline. Recent commentary around GlobalFoundries has focused on its role in the broader semiconductor supply chain and how...

In early 2026, Arcutis Biotherapeutics reported continued growth of its dermatology drug ZORYVE, outlined plans to broaden its use into vitiligo and hidradenitis suppurativa via ongoing Phase 2 trials, and launched clinical development of ARQ-234 for atopic dermatitis while moving toward positive cash flows to fund further research. This combination of expanding indications for an established product and the addition of a new biologic candidate suggests Arcutis is attempting to shift from a...

If you are wondering whether Progyny's current share price lines up with its underlying worth, you are not alone. That is exactly what this article will unpack. The stock recently closed at US$24.31, with returns of 17.9% over 1 year but declines of 11.4% over 7 days, 6.5% over 30 days, 5.6% year to date, 27.0% over 3 years and 48.6% over 5 years, which may have shifted how some investors think about its risk and reward profile. These mixed returns have kept Progyny on the radar for...

If you are wondering whether Teleflex's share price is starting to look interesting, this article walks through what the current market price could mean for long term value. The stock last closed at US$104.61, with returns of 4.9% decline over 7 days, 16.2% decline over 30 days, 14.5% decline year to date, 41.7% decline over 1 year, 54.5% decline over 3 years and 72.2% decline over 5 years, which may be changing how investors think about both risk and opportunity. Recent coverage around...

If you are wondering whether Snowflake's share price still reflects its long term potential or has run ahead of itself, looking closely at how the stock is valued can help frame your next move. Snowflake recently closed at US$207.74, with returns of 23.9% over 1 year and 53.6% over 3 years, while the last 7, 30 and year to date periods show returns of 7.2%, 5.8% and 4.1% declines respectively. Recent coverage has focused on Snowflake's role in cloud based data platforms and how investor...

Wondering if Alaska Air Group at around US$49.66 is a bargain or fairly priced today? This article breaks down what the current valuation suggests. The stock is up 2.2% over the last week, though it is down 5.3% over 30 days, 3.6% year to date, and 26.3% over the past year, so recent moves may look quite different depending on your time frame. Recent coverage of Alaska Air Group has focused on its share price performance and how the stock compares with peers within the broader airline...

Castle Biosciences (CSTL) kicked off 2026 with fresh guidance pointing to 2025 revenue above US$340 million, supported by double digit growth in core test volumes and closely watched by analysts. See our latest analysis for Castle Biosciences. The stock’s 90 day share price return of 84.06% and 1 year total shareholder return of 62.42% suggest momentum has been building, even though the 5 year total shareholder return of 49.49% is still negative. If Castle Biosciences’ update has you thinking...

Event snapshot and why Sphere Entertainment is on investors’ radar Sphere Entertainment (SPHR) is in focus after strong live event momentum around its Wizard of Oz production, fresh sponsorship deals, and the appointment of Felicia Yue as Executive Vice President and Chief Technology Officer for the Sphere division. See our latest analysis for Sphere Entertainment. Sphere Entertainment’s share price has been volatile, with a 10.22% 1 month share price return and a 64.29% 3 month share price...

If you are wondering whether Iovance Biotherapeutics is a beaten down biotech or a potential value opportunity, its current valuation story is worth taking a closer look at. The share price closed at US$2.22 most recently, and investors have seen a 14.9% decline over 7 days, 1.3% decline over 30 days, an 11.9% decline year to date, and a 61.5% decline over 1 year. This follows a 64.0% decline over 3 years and a 95.3% decline over 5 years. Recent news coverage around Iovance Biotherapeutics...

Investors may be wondering whether VICI Properties at around US$28.42 is offering good value right now, or if the easy gains are already behind it. The stock has returned 2.0% over the last 7 days, 0.4% over the last 30 days, 1.0% year to date, 2.7% over 1 year and 40.5% over 5 years, which provides a mix of short term moves and longer term context. Recent news coverage around VICI Properties has focused on its position as a major experiential real estate owner and its role within the US...